Adial Pharmaceuticals, Inc.
ADIL
$1.97
$0.147.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.64% | 5.36% | -9.75% | 9.33% | -20.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.85% | -20.23% | -17.69% | 22.89% | 8.80% |
| Operating Income | 2.85% | 20.23% | 17.69% | -22.89% | -8.80% |
| Income Before Tax | 3.60% | 18.16% | 20.33% | 65.59% | -8.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.60% | 18.16% | 20.33% | 65.59% | -8.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.60% | 18.16% | 20.33% | 65.59% | -7.84% |
| EBIT | 2.85% | 20.23% | 17.69% | -22.89% | -8.80% |
| EBITDA | 2.85% | 20.23% | 17.69% | -22.89% | -8.80% |
| EPS Basic | 77.39% | 78.46% | 68.63% | 84.46% | 60.76% |
| Normalized Basic EPS | 77.39% | 78.46% | 68.63% | 84.46% | 60.43% |
| EPS Diluted | 77.39% | 78.46% | 68.63% | 84.46% | 60.75% |
| Normalized Diluted EPS | 77.39% | 78.46% | 68.63% | 84.46% | 60.43% |
| Average Basic Shares Outstanding | 326.34% | 279.99% | 153.97% | 121.32% | 174.73% |
| Average Diluted Shares Outstanding | 326.34% | 279.99% | 153.97% | 121.32% | 174.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |